Market Overview
Size and treatment-linked demand
- Brevintel analysis projects obesity-related malnutrition nutrition demand from USD 242.2 million in 2026 ($242M) to USD 634.0 million by 2036 ($634M) at a 10.1% CAGR between 2026 and 2036.
- Headline cards list $242M (2026), $634M (2036), and 10.1% CAGR, matching the USD 242.2 million to USD 634.0 million narrative path.
- Growth stays narrower than the wider weight-management category because reduced intake can leave protein and micronutrient needs unresolved during active treatment.
- In May 2025, The Obesity Society and three partner organizations identified gastrointestinal effects, micronutrient deficiencies, and muscle or bone loss among practical GLP-1 treatment risks.
- Those risks give compact nutrient-dense products a defined role beside medication and supervised weight loss.
- The United States can convert demand through retail and direct online routes sooner than the staged UK public pathway.
- NHS England's April 2026 commissioning guidance phases tirzepatide access to approximately 220,000 patients after the first three years.
- UK nutrition companies gain a defined clinical recommendation point, but NHS volume builds more slowly than self-pay channels allow.
Commercial framing for companion nutrition
- Brevintel analysis frames the category as nutrient adequacy support during appetite suppression, not as a substitute for broad consumer weight-loss merchandising.
- Industry data suggests repeat purchasing depends on formats patients can store, tolerate, and reorder between appointments.
- Clinicians still set the nutrition objective while home and self-care settings determine whether recommendations become routine.
- Compact high-protein and micronutrient products address intake gaps without requiring a full meal during low-appetite periods.
- Self-pay retail and online routes can convert faster where public pharmacotherapy pathways stage access over multiple years.
- Serving tolerance, taste, and bottle volume influence multi-week acceptance when nausea and early satiety constrain intake.
- Education beside first purchase matters because companion nutrition must be explained before replenishment becomes habitual.
- Distribution depth after discharge or consultation keeps nutrition support continuous once clinical contact ends.
Market Dynamics
Drivers
- Pharmacotherapy can lower intake enough to expose protein and micronutrient risk during active obesity treatment.
- May 2025 guidance from The Obesity Society and partners elevated gastrointestinal effects, micronutrient deficiencies, and muscle or bone loss as practical GLP-1 treatment risks.
- Structured care pathways give targeted products a clearer recommendation point beside medication review.
- NHS England's April 2026 tirzepatide commissioning path covering approximately 220,000 patients after three years creates a defined clinical entry point in the UK.
- Home / self-care demand supports repeated protein and micronutrient use outside formal care settings.
- Danone completed its majority acquisition of Kate Farms in July 2025, extending specialized nutrition reach across hospitals, home, online, and shelf.
- Danone Nutricia launched Fortimel Plantbased Protein in February 2025, widening plant-based high-protein oral options for disease-related malnutrition.
- Medifast introduced OPTAVIA ASCEND in January 2025 with high-protein mini meals, a daily nutrient pack, and coaching plans for GLP-1 users.
Restraints and pathway filters
- Uneven funding can interrupt repeat use even when clinicians recommend targeted nutrition.
- NHS volume builds more slowly than self-pay retail and direct online channels allow in faster-converting markets.
- Household cost keeps refill affordability sensitive during longer pharmacotherapy courses without routine insurance coverage for nutrition packs.
- Weak differentiation from ordinary shakes can interrupt longer-term replenishment in the United States.
- German household cost keeps protein and micronutrient claims under close scrutiny after counseling and pharmacy recommendation.
- Japan keeps GLP-1 obesity treatment inside approved medical indications, so qualifying patient flow constrains volume.
- MHLW's June 2026 notice warned against cosmetic or other off-label use and restated semaglutide eligibility at BMI 35 kg/m2 or BMI 27 kg/m2 with two related health disorders after inadequate diet and exercise response.
- Taste, serving size, and early satiety remain practical barriers to multi-week RTD and powder routines.
Segmentation Analysis
Product type and context
- The market is segmented by product type, context, product form, end user, sales channel, and region.
- Product type covers high-protein low-calorie ONS, micronutrient repletion blends, GLP-1 companion nutrition, protein-sparing meal products, and others.
- By product type, high-protein low-calorie ONS is estimated to hold 43.3% in 2026 owing to concentrated protein delivery within controlled energy intake.
- High-protein low-calorie ONS addresses the central trade-off: energy intake can fall faster than protein needs without requiring a full meal.
- Context includes GLP-1 / pharmacotherapy users, post-bariatric surgery, sarcopenic obesity, and other treatment settings.
- In 2026, GLP-1 / pharmacotherapy users are expected to lead context with 48.9% share because reduced intake makes nutrient adequacy a treatment-side purchasing issue.
- Companion products must close the intake gap without undermining the medicine's weight-loss objective.
- Medifast's January 2025 OPTAVIA ASCEND offer linked nutrition support to medication use and post-loss weight maintenance.
Product form and end user
- Product form separates RTD, powders, puddings and semi-solids, and other preparation formats.
- RTD is projected to hold 49.9% of product form demand in 2026 owing to immediate use and fixed serving size during low-appetite periods.
- RTD formats remove preparation from a use case constrained by nausea, early satiety, and low appetite.
- Fresenius Kabi's December 2025 year review recorded the 2025 launch of Fresubin PLANT-BASED Drink as a ready-to-use high-protein oral supplement.
- End users include home / self-care, obesity clinics and hospitals, and other care settings.
- Home / self-care is set to lead the end user category with 54.7% share in 2026 due to repeated protein and micronutrient use outside formal care settings.
- Most companion nutrition is consumed between appointments, so the home determines whether a clinical recommendation becomes routine.
- Patients need formats they can store, tolerate, and reorder without another visit while clinicians set the nutrition objective.
Sales channel
- Sales channels include online / DTC, retail pharmacy, supermarkets and hypermarkets, specialty and health stores, and others.
- By sales channel, online / DTC is forecast to represent 40.2% in 2026 driven by education, direct fulfillment, and repeat ordering within one purchase path.
- Direct online selling fits a category that needs explanation before the first order and low friction after it.
- Subscription timing can follow the patient's actual use rate as appetite and tolerance shift.
- Medifast's February 2026 Form 10-K states that its direct-to-consumer model ships products directly to clients with coach support in one commercial relationship.
- Retail pharmacy remains important where clinical counseling and serving-cost comparisons shape self-pay decisions.
- Supermarkets, hypermarkets, and specialty health stores support pack discovery after digital education or clinic recommendation.
- Brevintel analysis expects online / DTC to stay central while pharmacy and retail sustain clinically framed replenishment.
Regional Outlook
Country growth band
- The five forecasts form three bands over a 2.1 percentage-point range.
- South Korea and the UK occupy the upper band, USA and Germany form the middle, and Japan sits lower at 8.3%.
- The spacing reflects different treatment-channel formation and consumer conversion, not current revenue scale alone.
- Obesity-related malnutrition nutrition demand in South Korea is forecast to rise at 10.4% CAGR over the forecast period because direct purchasing permits smaller packs while household cost keeps repeat use sensitive to price.
- KDCA reported in November 2025 that 34.4% of adults had obesity in the 2024 Community Health Survey, with prevalence 30.8% higher than a decade earlier.
- South Korea's large self-pay obesity-care base means targeted nutrition must prove serving value without assuming routine insurance coverage.
- The UK obesity-related malnutrition nutrition sector is projected to record 9.8% CAGR during the assessment period because nationally specified care steps can standardize counseling.
- NHS England's February 2026 GP contract introduced OB005 with a 50-80% achievement threshold for shared decision-making and obesity pharmacotherapy.
USA, Germany, and Japan
- United States obesity-related malnutrition nutrition demand is forecast to post 9.5% CAGR through 2036 supported by broad self-care access.
- NCHS documented in February 2026 that 40.3% of adults aged 20 and older had obesity during August 2021 to August 2023.
- USA purchases begin in obesity clinics, primary care, retail stores, and direct online channels while fragmented payment leaves brands to prove repeat-purchase value.
- Germany's obesity-related malnutrition nutrition outlook is anticipated to advance at 9.2% CAGR over the assessment period tied to clinical counseling and pharmacy access.
- Robert Koch Institute data published in March 2025 show adult obesity prevalence increased from 12.2% in 2003 to 19.7% in 2023.
- In Japan, obesity-related malnutrition nutrition demand is predicted to advance at 8.3% CAGR through 2036 given tightly supervised pharmacotherapy.
- Japan favors clinician-framed protein and micronutrient products over broad consumer weight-loss merchandising.
- Similar CAGRs still produce different entry conditions because payment ownership varies across these national markets.
Broader regional coverage
- Brevintel analysis covers country-level CAGR pathways across North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East and Africa.
- South Korea: mobile commerce speeds pack-size and refill testing for self-pay nutrition brands.
- UK: national guidance can standardize nutrition advice for patients entering pharmacotherapy services.
- USA: retail breadth shortens access despite fragmented clinical recommendation and payment routes.
- Germany: pharmacy credibility sharpens comparisons between clinical purpose and household serving cost.
- Japan: medical-nutrition channels favor clinically framed products over broad consumer weight-loss merchandising.
- Industry data suggests refill affordability and clinical framing remain binding commercial filters worldwide.
- Regional attractiveness hinges on pathway formation, self-pay conversion, and serving economics rather than headline CAGR alone.
Competitive Landscape
Competitive structure
- Abbott (Protality), Nestle Health Science, Danone Nutricia, Medifast (OPTAVIA), Fresenius Kabi, Medtrition, Victus, and Celebrate Vitamins are notable companies serving this market.
- Competition centers on compact protein delivery, micronutrient repletion, and GLP-1 companion formats that fit low-appetite routines.
- Danone's July 2025 Kate Farms majority acquisition deepened specialized-nutrition distribution across hospital, home, online, and shelf routes.
- Danone Nutricia's February 2025 Fortimel Plantbased Protein launch widened plant-based high-protein oral choices.
- Medifast's January 2025 OPTAVIA ASCEND and February 2026 DTC disclosures link coaching, mini meals, and direct shipping for GLP-1 users.
- Fresenius Kabi's 2025 Fresubin PLANT-BASED Drink launch extended ready-to-use high-protein medical nutrition options.
- Brevintel analysis expects winning positions to convert clinic recommendations into home reorder routines within the 54.7% home / self-care and 40.2% online / DTC shares.
- Differentiation rests on clinical purpose, serving tolerance, and refill economics rather than broad weight-loss branding alone.
Integrated producers
- Abbott (Protality)
- Nestle Health Science
- Danone Nutricia
- Fresenius Kabi
Specialty suppliers
- Medifast (OPTAVIA)
- Medtrition
- Victus
- Celebrate Vitamins